information on concomitant and adjuvant treatment such as physiotherapy are rarely specified or described in detail.
The aim of the present study was to conduct a cross-sectional study on current practice in management of muscle bleeds in patients with severe Haemophilia A amongst haemophilia comprehensive care centres from UK, Denmark, Ireland, and Australia based on an electronic mail questionnaire. 
Ethical considerations
The data from each participant are anonymous; hence, none of the results can be referred back to a specific centre. The questionnaire did not include specific patient data.
Results

Frequency and aetiology of muscle bleeding
In total 22 consultants representing 20 comprehensive haemophilia care centres in UK (17) , IR (1), DK (2), and AUS (2) 
Diagnostic procedures
Half of the respondents stated they distinguish between contusion and strains, whereas the majority (68.2%) did not categorise bleedings as intra-or intermuscular, although 77.3% routinely used diagnostic ultrasound.
Haemostatic intervention
Only 50 % of respondents reported using a standard protocol for management of muscle haematomas. The questionnaire outlined a theoretical case: "An objectively verified muscle haematoma in the soleus triceps of a lower limb of a 29 year old patient, weighing 70 kilos with severe Haemophilia A." followed by questions addressing i) initial dosages of factor, ii) subsequent dosages of factor, iii) duration of therapy, iv) tapering of dosages or dose frequency, as well as v) addition of an anti-fibrinolytic.
Haemostatic intervention in patients with severe Haemophilia A without inhibitor
The average initial dose of factor VIII was 2730 U (range: 1750-4000).
Treatment was continued for a mean of 3-5 days (range: 1-10). Subsequent dosages were similar to the initial dosage, although the majority of respondents indicated they were tapering the dosage and dose frequency based on daily assessment of each individual case. The majority (77.3%) of consultants did not distinguish recombinant factor VIII from plasma derived factor VIII concentrate containing von Willebrand factor. The total amount of factor VIII used ranged from minimum=4500 U to maximum=50000 U (median=10750 U, mean=17103 U) depending on the severity, type and anatomical localisation of the haematoma.
Haemostatic intervention in patients with severe Haemophilia A with inhibitors
In a similar case of a patient with inhibitors, 31.8% reported first line and only use of either recombinant factor VIIa (rFVIIa) or plasma derived activated prothrombin complex concentrate (pd-aPCC), while 36.4% switched between bypassing agents. Using rFVIIa the median starting dose was 100 µg/kg (range:
85 -270) and with aPCC the median dose was 70 U/kg (range: 50 -100).
Subsequent dosages ranged from 85-270 µg/kg for rFVIIa (mean=110) and 50-75 U/kg (mean=63) for pd-aPCC. Dosing interval was 2-3 hrs for rFVIIa and 12-24 hrs for pd-aPCC. The average duration of treatment was 2.3 -4.4 days, longer for pd-aPCC (4.1 days) than rFVIIa (2.8 days). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 showing that pain was scored as the most important marker.
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Physiotherapy
A total of 20 of 22 (90.9%) offered physiotherapy in the hospital following muscle haematomas. As outlined in Table 1 , there was limited consensus on timing and type of treatment. RICE-treatment (rest-ice-compression-elevation) was recommended in most centres. All centres offered therapeutic ultrasound in the hospital setting, although there was limited agreement on the optimal timing of the intervention.
Grading of importance of further research and studies in management of muscle haematoma in patients with Haemophilia
The overall importance of further research and studies in management of muscle haematomas scored 7 and 8 (out of 10) for haemophilia patients without and with inhibitors. Currently, limited consensus exists on the comprehensive management of muscle haematomas in Haemophilia patients.
The present survey verified that the majority of muscle haematomas has a traumatic aetiology. It may be speculated whether patients with inhibitors are more prone to develop muscle haematomas than patients without inhibitors.
Some studies suggest that muscle haematomas represent 10% of all bleeds in patients with severe Haemophilia [1] . However, the data from the US home treatment study of rFVIIa suggest that up to 23% of bleeds in patients with inhibitors are muscle haematoma [11] . These questions were not explored in further detail in the present study, however, should be kept in mind for future investigations.
Not surprisingly, iliopsoas muscle bleeds were reported as the most severe type of muscle haematoma. Likewise, the majority of previous reports and studies have focused on the iliopsoas bleeds [6;7] .
The study revealed sparse consistency regarding diagnostic procedures. Only half of the respondents distinguished contusions from strains. The majority of centres listed the use of ultrasound for diagnosis. However, only few differentiated between intra-vs. inter-muscular localisation of the haematoma.
Diagnostic classification of muscle haematomas is a complicated clinical discipline and in the current issue of Haemophilia we have reviewed classification and strategies for optimised diagnosis of muscle haematomas [12] .
Moreover, the questionnaire highlighted limited agreement regarding dosing regimens and duration of the pharmacological therapy. Only half of respondents stated to have a specific written protocol on recommendations for coagulation factor treatment of muscle bleeds. Thus, the total amount of factor VIII used 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 following muscle injuries may take more than 30 days [13] . Pain may be considered a physiological response to muscle damage and present despite arrest of bleeding and normal haemostasis. Hence, it seems that optimised measures for assessing ongoing bleeding and achieved haemostasis are essential for optimising treatment regimens.
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The majority of participants indicated a time period of less than 6 hrs as the preferred / accepted time to arrest of bleeding. There was a slight tendency to accept of longer time to arrest of bleeding in patients with inhibitors. This may be due to less predictability regarding haemostatic response as well as difficulties in monitoring and dosing the bypassing agents.
Recently investigations have shown that patients with severe Haemophilia not only suffer from compromised thrombin generation, but also insufficient clot stability caused by delayed and incomplete activation of FXIII [14] and increased susceptibility toward accelerated fibrinolysis [15] . Clinical studies have suggested a potent effect of concomitant antifibrinolytic treatment with tranexamic acid [15] . However, the majority of responders in the survey stated not to use adjuvant tranexamic acid for muscle haematoma. The study did not explore reasons for limited use of tranexamic acid. Lack of clinical studies may be one reason, whereas theoretical speculations on thrombotic risk may be another explanation. Further mechanistic as well as clinical studies would be desirable.
The timing and type of adjuvant physiotherapy recommended revealed considerable discrepancy. The RICE principle and therapeutic ultrasound was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [12] . Recent publications have proposed a beneficial and potentially protective effect of regular exercise in patients with severe Haemophilia [16] . Optimized muscular function may protect against joint bleedings and improved fitness was associated with a higher rating of quality of life [17] [18] [19] . Likewise, a recent study describe a conservative and non-operative physiotherapeutic regime for the management of chronic haematomata and pseudotumors in patients suffering from haemophilia [20] .
The study contains a series of important limitations. This cross sectional study only provides a random sample of current management of muscle haematomas.
The nature of the study design does not provide valid data on causality, neither In conclusion, the present survey suggests the need for further studies on the pathology, diagnosis, and importance of early treatment to achieve rapid control of bleeding, as well as rehabilitation following muscle haematomas in patients with Haemophilia. A prospective international multicentre registry of current management of muscle haematomas seems desirable to get more data.
Optimised and systematic diagnosis may facilitate a better strategy regarding type and timing of physiotherapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Markers of arrest of bleeding and maintaining haemostasis
Illustrates the results of score of importance of the three clinical markers: reduced pain, reduced swelling, improved range of motion as defined by subjective reported relief of pain, reduced circumferential measure, and measurement of the achievable distance between the flexed position and the extended position of a particular muscle group, respectively. The score 1 corresponds most important, whereas the score 3 corresponds least important. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w Tables   Table 1   Timing 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 Legends Table 1 Timing and type of physiotherapy
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Lists the recommended type of physiotherapy at various time intervals: 0-24hrs, 24-72hrs, 4-21 days, and >21 days. Data show number of responders as well as the frequency in percentages. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 
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